ES2324876T3 - Composiciones y metodos para el diagnostico de tumores. - Google Patents

Composiciones y metodos para el diagnostico de tumores. Download PDF

Info

Publication number
ES2324876T3
ES2324876T3 ES05019849T ES05019849T ES2324876T3 ES 2324876 T3 ES2324876 T3 ES 2324876T3 ES 05019849 T ES05019849 T ES 05019849T ES 05019849 T ES05019849 T ES 05019849T ES 2324876 T3 ES2324876 T3 ES 2324876T3
Authority
ES
Spain
Prior art keywords
acid sequence
amino acid
polypeptide
identity
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05019849T
Other languages
English (en)
Inventor
David Botstein
Audrey Goddard
Austin L Gurney
Margaret Ann Roy
Colin K Watanabe
William I Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/en
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2324876T3 publication Critical patent/ES2324876T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01133—Xylosylprotein 4-beta-galactosyltransferase (2.4.1.133)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Método para determinar la presencia de un polipéptido PR04407 en una muestra sospechosa de contener dicho polipéptido, comprendiendo dicho método exponer la muestra a un anticuerpo anti-PR04407 y determinar la unión de dicho anticuerpo a dicho polipéptido en dicha muestra; donde dicha muestra comprende células de pulmón, colon, mama o paratiroides obtenidas de un individuo del que se sospecha que tiene crecimiento o proliferación de células neoplásicas, y donde dicho polipéptido PRO4407 es un polipéptido: a) que tiene al menos el 80% de identidad en la secuencia de aminoácidos con una secuencia de aminoácidos seleccionada entre el grupo que consiste en la secuencia de aminoácidos mostrada en la Figura 2 (SEC ID Nº: 47); b) que da una valoración al menos el 60% de positivos cuando se compara con una secuencia de aminoácidos seleccionada entre el grupo que consiste en la secuencia de aminoácidos mostrada en la Figura 2 (SEC ID Nº: 47); c) que tiene al menos el 80% de identidad en la secuencia de aminoácidos con una secuencia de aminoácidos codificada por la secuencia codificante de longitud completa de la secuencia de ácido nucleico DNA 92264- 2616 depositada con el número de entrada en la ATCC 203969; d) que tiene al menos el 80% de identidad en la secuencia de aminoácidos con el polipéptido mostrado en la Figura 2 (SEC ID Nº: 47), que carece de su péptido señal asociado; e) que tiene al menos el 80% de identidad en la secuencia de aminoácidos con un dominio extracelular del polipéptido mostrado en la Figura 2 (SEC ID Nº: 47), con su péptido señal asociado; o f) que tiene al menos el 80% de identidad en la secuencia de aminoácidos con un dominio extracelular del polipéptido mostrado en la Figura 2 (SEC ID Nº: 47), que carece de su péptido señal asociado donde la identidad en la secuencia se calcula usando el programa ALIGN-
ES05019849T 1999-03-08 1999-12-02 Composiciones y metodos para el diagnostico de tumores. Expired - Lifetime ES2324876T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
PCT/US1999/020111 WO2000012708A2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
US16250699P 1999-10-29 1999-10-29
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization

Publications (1)

Publication Number Publication Date
ES2324876T3 true ES2324876T3 (es) 2009-08-18

Family

ID=29215742

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05019849T Expired - Lifetime ES2324876T3 (es) 1999-03-08 1999-12-02 Composiciones y metodos para el diagnostico de tumores.
ES05019847T Expired - Lifetime ES2329689T3 (es) 1999-03-08 1999-12-02 Composiciones y procedimientos para el diagnostico de tumores.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05019847T Expired - Lifetime ES2329689T3 (es) 1999-03-08 1999-12-02 Composiciones y procedimientos para el diagnostico de tumores.

Country Status (9)

Country Link
EP (6) EP1642968B1 (es)
JP (7) JP2003525585A (es)
KR (5) KR100543857B1 (es)
AT (2) ATE427319T1 (es)
AU (4) AU773055C (es)
CA (1) CA2367334A1 (es)
DE (2) DE69941273D1 (es)
ES (2) ES2324876T3 (es)
WO (1) WO2000053750A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914130B2 (en) * 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2356548A1 (en) * 1998-12-23 2000-07-06 Human Genome Sciences, Inc. Human brainiac-5
AU1342501A (en) * 1999-10-29 2001-05-14 Human Genome Sciences, Inc. 32 human secreted proteins
WO2001066720A1 (fr) * 2000-03-10 2001-09-13 Toshio Kitamura Genes de souris d'origine adipocyte
WO2002002774A2 (en) * 2000-06-30 2002-01-10 Millennium Pharmaceuticals, Inc. 32626, a human udp-glycosyltransferase and uses thereof
CA2416538A1 (en) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2006514531A (ja) * 2001-02-16 2006-05-11 インサイト・ゲノミックス・インコーポレイテッド 薬物代謝酵素
GB0110273D0 (en) * 2001-04-26 2001-06-20 Inpharmatica Ltd Novel proteins
JP2004147542A (ja) * 2002-10-30 2004-05-27 National Institute Of Advanced Industrial & Technology 糖転移酵素及びそれをコードする核酸、並びに該核酸を用いた癌組織の検出方法
AU2006223579A1 (en) * 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP2009131151A (ja) * 2006-02-28 2009-06-18 Osaka Univ ＰＩＬＲαと結合するポリペプチド、およびそれをコードするポリヌクレオチド、並びにその利用
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
EP2621514B1 (en) 2010-09-28 2016-09-21 KAHR Medical (2005) Ltd Compositions and methods for treatment of hematological malignancies
CN104342444B (zh) * 2013-07-23 2017-11-17 四川大学华西医院 一种重组trail蛋白及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965362A (en) * 1992-03-04 1999-10-12 The Regents Of The University Of California Comparative genomic hybridization (CGH)
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
DE69333202T2 (de) * 1992-06-26 2004-03-18 The Trustees Of Princeton University Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden
CA2296815A1 (en) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. 64 human secreted proteins
AU758004B2 (en) * 1997-12-17 2003-03-13 Genset S.A. Extended cDNAs for secreted proteins
WO1999031116A1 (en) * 1997-12-18 1999-06-24 Human Genome Sciences, Inc. Human dendriac and brainiac-3
EP1040117A4 (en) * 1997-12-18 2005-03-09 Human Genome Sciences Inc 110 HUMAN SECRETED PROTEINS
ES2312205T3 (es) * 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
EP1080194A2 (en) * 1998-05-29 2001-03-07 Incyte Pharmaceuticals, Inc. Human transmembrane proteins
EP1097199A4 (en) * 1998-07-15 2005-02-23 Human Genome Sciences Inc 71 HUMAN SECRETED PROTEINS
WO2000029448A2 (en) * 1998-11-17 2000-05-25 Sagami Chemical Research Center Human proteins having hydrophobic domains and dnas encoding these proteins
IL142794A0 (en) * 1998-12-16 2002-03-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2356548A1 (en) * 1998-12-23 2000-07-06 Human Genome Sciences, Inc. Human brainiac-5
CA2358804A1 (en) * 1999-01-12 2000-07-20 Zymogenetics, Inc. Human beta-1,3-galactosyltransferase homolog, znssp6
KR100468976B1 (ko) * 1999-02-10 2005-02-02 제넨테크, 인크. 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
JP2004507202A (ja) * 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
EP1197556A4 (en) * 1999-06-29 2003-01-22 Kyowa Hakko Kogyo Kk USEFUL POLYPEPTIDES
WO2001002568A2 (en) * 1999-07-02 2001-01-11 Chiron Corporation Human genes and gene expression products
JP2002017375A (ja) * 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 全長ｃＤＮＡ合成用プライマー、およびその用途
EP1130094A3 (en) * 1999-07-08 2001-11-21 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
AU7680300A (en) * 1999-08-18 2001-03-13 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Human dna sequences
CA2384499A1 (en) * 1999-09-10 2001-03-15 Corixa Corporation Ovarian tumor sequences and methods of use therefor
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides

Also Published As

Publication number Publication date
KR20040088077A (ko) 2004-10-15
JP2003525585A (ja) 2003-09-02
JP2009039097A (ja) 2009-02-26
WO2000053750A1 (en) 2000-09-14
AU2004201759A1 (en) 2004-05-20
EP1642906A2 (en) 2006-04-05
AU2004201769A1 (en) 2004-05-27
AU773055C (en) 2004-12-02
CA2367334A1 (en) 2000-09-14
EP1642967A3 (en) 2006-07-26
AU3107700A (en) 2000-09-28
JP2003274979A (ja) 2003-09-30
KR100543857B1 (ko) 2006-01-23
ES2329689T3 (es) 2009-11-30
EP1642967A2 (en) 2006-04-05
KR100473551B1 (en) 2005-03-14
AU773055B2 (en) 2004-05-13
KR100473550B1 (en) 2005-03-15
JP2003274977A (ja) 2003-09-30
EP1634892A2 (en) 2006-03-15
DE69940681D1 (de) 2009-05-14
EP1642968B1 (en) 2009-08-12
KR20040077790A (ko) 2004-09-06
DE69941273D1 (de) 2009-09-24
KR20020008123A (ko) 2002-01-29
JP2003274978A (ja) 2003-09-30
EP1642968A3 (en) 2006-06-21
JP2003274980A (ja) 2003-09-30
KR20050004773A (ko) 2005-01-12
ATE427319T1 (de) 2009-04-15
JP2009000114A (ja) 2009-01-08
EP1642907A3 (en) 2006-06-21
ATE439431T1 (de) 2009-08-15
EP1642906A3 (en) 2006-07-26
EP1642968A2 (en) 2006-04-05
KR100517848B1 (en) 2005-09-30
KR20040073588A (ko) 2004-08-19
EP1642907A2 (en) 2006-04-05
KR100566839B1 (ko) 2006-04-03
EP1159422A1 (en) 2001-12-05
EP1642907B1 (en) 2009-04-01
AU2004201769B2 (en) 2007-07-19
AU2004201759B2 (en) 2007-07-19
EP1634892A3 (en) 2006-06-21
AU2004201760B2 (en) 2007-07-19
AU2004201760A1 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
ES2525677T3 (es) Celulasas, genes que las codifican y usos de las mismas
ATE321849T1 (de) Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
WO2001055320A3 (en) Nucleic acids, proteins, and antibodies
ES2218872T3 (es) Polipeptido 10 de tipo citoquina de mamifero.
CA2414331A1 (en) Pd-l2 molecules: novel pd-1 ligands and uses therefor
NO20001668D0 (no) Anvendelse av et DNA-fragment, samt komplementære kjeder, derivater og deler derav
DE69840966D1 (de) Homolog NL6 des Tie Rezeptor Tyrosinekinase Liganden
ES2329689T3 (es) Composiciones y procedimientos para el diagnostico de tumores.
AR014233A1 (es) Metodo para el control del perforante europeo del maiz (ostrinia nubilalis)
PL327066A1 (en) Method of diagnosing and treating squamous cell carcinomas
WO2002026930A3 (en) Nucleic acids, proteins, and antibodies
AU8503898A (en) Monospecific antibody reactive with fibrinogen and fibrinopeptide
JP2005535289A5 (es)
DE60331882D1 (de) Antikörper zur Identifizierung und/oder Isolierung von wenigstens einer Zellpopulation ausgewählt aus hämatopoetischen Stammzellen, neuronalen Stammzellen, progenitoren neuronalen Zellen, Mesenchym-Stammzellen und mesenchym-progenitoren Stammzellen
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
WO2002008280A3 (en) SCREENING METHODS BASED ON SUPERACTIVATED αVβ3 INTEGRIN
JP2005525112A5 (es)
WO2001095860A3 (en) Probes for chondrogenesis
JP2005516604A5 (es)
DK0773999T3 (da) OR-1, en orphan-receptor tilhørende kernereceptorfamilien
AR018045A1 (es) Proteina placentaria 13 y polipetido, molecula de adn que los codifica, anticuerpos capaces de enlazarse a ellos, metodo para la deteccion decomplicaciones relacionadas con el embarazo, metodo recombinante para la produccion de dicha proteina y un equipo para el diagnostico de complicacionesrelacion
ATE318933T1 (de) Nukleinsäurefragmente zur identifizierung von dechlorierenden bakterien
AR012252A1 (es) Un metodo para identificar agentes que se unen a un receptor de toxina bt y que bloquean la union de una toxina bt; un anticuerpo aislado; una proteinareceptora aislada de toxina bt y un metodo para producirla